Advanced Prostate Cancer
39
12
15
10
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
5.1%
2 terminated out of 39 trials
83.3%
-3.2% vs benchmark
15%
6 trials in Phase 3/4
50%
5 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (39)
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
Lab Research Using Mini-tumors to Study Prostate Cancer Treatments
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
Engage Psychosocial Intervention for Cancer Symptoms
A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer
PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer.
Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)
SRAM study_Postate Cancer
Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer
Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer
Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart.
Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer
Whole Body MRI in Oncology
Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer
European Registry of Next Generation Imaging in Advanced Prostate Cancer